Skip to content
Link copied to clipboard

Biopharma firm Adaptimmune to relocate U.S. operations to Navy Yard

Adaptimmune, an Oxford, U.K.-based biopharmaceutical company, has moved its U.S. operations from the University City Science Center and will relocate to a new facility at the Philadelphia Navy Yard, the company said Friday.

Adaptimmune, an Oxford, U.K.-based biopharmaceutical company, has moved its U.S. operations from the University City Science Center and will relocate to a new facility at the Philadelphia Navy Yard, the company said Friday.

The 47,400-square-foot building being developed by Liberty Property Trust and Synterra Partners will accommodate a manufacturing plant and Adaptimmune's U.S. headquarters, according to the company, which focuses on cancer therapies.

The new facility, which will enable Adaptimmune to increase its staff by 110, is scheduled to be completed in late 2016, chief executive James Noble said in the release.

The company has taken office space at Two Commerce Square, 2001 Market St., in the interim.

Adaptimmune plans to invest more than $4 million at the new facility, according to a separate statement from Gov. Wolf's office.

jadelman@phillynews.com

215-854-2615 @jacobadelman